Physician profile
Jacinth E Brooks
NPI 1225117211
$1,983.78
in general payments reported to CMS, 2019-2025
36 companies · $545 in 2025
The $545 reported for 2025 was more than what 85% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.08 · 2021: $401 · 2022: $550 · 2023: $76.03 · 2024: $321 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $942.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $316.95 | 2020-2022 | |
| Novo Nordisk INC | $257.61 | 2021-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $198.13 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $145.22 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $138.83 | 2020-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $83.51 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Astellas Pharma US INC | $69.98 | 2022-2025 | Veozah |
| Glaxosmithkline, LLC. | $67.66 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $54.00 | 2022 | |
| Abbott Laboratories | $44.93 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $44.49 | 2021-2022 | |
| Amarin Pharma, INC. | $43.64 | 2022 | |
| Corcept Therapeutics | $41.43 | 2022-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $39.47 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.84 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $29.50 | 2020-2022 | |
| Integra Lifesciences Corporation | $26.25 | 2025 | Trudi Probe, Inspira Air, Acclarent Aera |
| Genentech USA, INC. | $24.83 | 2021 | |
| Hologic Sales and Service, LLC | $24.00 | 2025 | Aptima, Thinprep 2000 Processor |
| Philips North America LLC | $22.93 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Horizon Therapeutics Plc | $22.14 | 2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $21.26 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $20.88 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $19.80 | 2025 | Neffy |
| Amgen INC. | $19.75 | 2024 | Krystexxa |
| Allergan, INC. | $19.16 | 2020 | |
| Sanofi Pasteur INC. | $19.05 | 2025 | |
| Eisai INC. | $17.35 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.59 | 2025 | Gvoke Hypopen |
| Optinose US, INC. | $16.49 | 2024 | |
| Seqirus USA INC | $15.66 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $15.47 | 2021 | |
| Kaleo, INC. | $15.17 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.31 | 2021 | |
| Medtronic, INC. | $13.78 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacinth Brooks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.